Bioequivalence accomplishments, ongoing initiatives, and remaining challenges

Journal of Veterinary Pharmacology and Therapeutics

Volumn 37, Issue 1, 2014, Pages 2-12

  Martinez, M N ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; CILOSTAZOL; VETERINARY DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG SOLUBILITY; EXPERIMENTAL DOG; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; VETERINARY MEDICINE;

ANIMALS; SPECIES SPECIFICITY; THERAPEUTIC EQUIVALENCY; VETERINARY DRUGS; VETERINARY MEDICINE;

EID: 84892144074     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/jvp.12063     Document Type: Article

References (40)

1. Amidon, G.L., Lennernäs, H., Shah, V.P. & Crison, J.R. (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12, 413-420.
2. Annon1 (2009) ICH harmonised tripartite guideline pharmaceutical development Q8(R2). Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf (accessed 23 March 2013).
3. Annon2 (2000) US FDA, Center for Drug Evaluation and Research. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070246.pdf (accessed 23 March 2013).
4. Annon3 (2008) European medicines agency guideline on the investigation of bioequivalence. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003011.pdf (accessed 23 March 2013).
5. Annon4 (2012) Health Canada draft guidance document: biopharmaceutics classification based biowaiver. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/consultation/drug-medic/bcs_draft_guide_ebauche_ld_scb-eng.pdf (accessed 23 March 2013).
6. Annon5 (2012) Introduction to a general chapter for veterinary products posted for comment, workshop scheduled. Available from: http://www.usp.org/usp-nf/notices/introduction-general-chapter-veterinary-products-posted-comment-workshop-scheduled (accessed 23 March 2013).
7. Annon6 (2012) FDA news release: FDA issues draft guidance on biosimilar product development. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm291232.htm (accessed 23 March 2013).
8. Annon7 (2012) U.S. FDA center for drug evaluation and research and center for biologics evaluation and research, guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product: draft guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf (accessed 23 March 2013).
9. Annon8 (2012) U.S. FDA center for drug evaluation and research and center for biologics evaluation and research, guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product: draft guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed 23 March 2013).
10. Annon9 (2012) U.S. FDA center for drug evaluation and research and center for biologics evaluation and research, guidance for industry: biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act of 2009. Draft Guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf (accessed 23 March 2013).
11. Apley, M., Crist, B., Gonzalez, M.A., Hunter, R.P., Martinez, M.N., Modric, S., Papich, M.G., Parr, A.R., Riviere, J.E. & Marques, M.R.C. (2012) Stimuli to the revision process. Available from: http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/s200600.pdf (accessed 23 March 2013).
12. Blume, H.H., McGilveray, I.J. & Midha, K.K. (1995) Bio-international 94, conference on bioavailability, bioequivalence and pharmacokinetic studies. European Journal of Pharmaceutical Sciences, 3, 113-124.
13. Claxton, R., Cook, J., Endrenyi, L., Lucas, A., Martinez, M.N. & Sutton, S.C. (2012) Estimating product bioequivalence for highly variable veterinary drugs. Journal of Veterinary Pharmacology and Therapeutics, 35 (Suppl. 1), 11-16.
14. Declerck, P.J. & Simoens, S. (2012) A European perspective on the market accessibility of biosimilars. Biosimilars, 2, 33-40.
15. Dressman, J.B., Amidon, G.L., Reppas, C. & Shah, V.P. (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharmaceutical Research, 15, 11-22.
16. Endrenyi, L. & Tothfalusi, L. (2010) Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products? Journal of Pharmacy & Pharmaceutical Sciences, 13, 107-113.
17. Gehring, R. & Martinez, M. (2012) Assessing product bioequivalence for extended-release formulations and drugs with long half-lives. Journal of Veterinary Pharmacology and Therapeutics, 35 (Suppl. 1), 3-9.
18. Haidar, S.H., Davit, B., Chen, M.L., Conner, D., Lee, L., Li, Q.H., Lionberger, R., Makhlouf, F., Patel, D., Schuirmann, D.J. & Yu, L.X. (2008) Bioequivalence approaches for highly variable drugs and drug products. Pharmaceutical Research, 25, 237-241.
19. Hauck, W.W. & Anderson, S. (1994) Measuring switchability and prescribability: when is average bioequivalence sufficient? Journal of Pharmacokinetics and Biopharmaceutics, 22, 551-564.
20. Holford, N.H. & Sheiner, L.B. (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics, 6, 429-453.
21. Jinno, J., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G.G., Higaki, K. & Kimura, T. (2006) Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. Journal of Controlled Release, 111, 56-64.
22. Kaeser, B., Charoin, J.E., Gerber, M., Oxley, P., Birnboeck, H., Saiedabadi, N. & Banken, L. (2005) Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics, 43, 154-162.
23. Lainesse, C. (2012) International veterinary bioequivalence guideline similarities and differences between Australia, Canada, Europe, Japan, New Zealand and the United States. The AAPS Journal, 14, 792-798.
24. Lifschitz, A., Pis, A., Alvarez, L., Virkel, G., Sanchez, S., Sallovitz, J., Kujanek, R., & Lanusse, C. (1999) Bioequivalence of ivermectin formulations in pigs and cattle. Journal of Veterinary Pharmacology and Therapeutics, 22, 27-33.
25. Martinez, M.N. (2011) Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems. The AAPS Journal, 13, 632-649.
26. Martinez, M.N. & Apley, M.D. (2012) Drug solubility classification in the bovine. Journal of Veterinary Pharmacology and Therapeutics, 35 (Suppl. 1), 93-97.
27. Martinez, M.N. & Fahmy, R. (2012) The scientific basis for establishing solubility criteria for veterinary species. Journal of Veterinary Pharmacology and Therapeutics, 35 (Suppl. 1), 81-86.
28. Martinez, M.N. & Hunter, R.P. (2010) Current challenges facing the determination of product bioequivalence in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics, 33, 418-433.
29. Martinez, M.N., Pedersoli, W.M., Ravis, W.R., Jackson, J.D. & Cullison, R. (2001) Feasibility of interspecies extrapolation in determining the bioequivalence of animal products intended for intramuscular administration. Journal of Veterinary Pharmacology and Therapeutics, 24, 125-135.
30. Martinez, M., Amidon, G., Clarke, L., Jones, W.W., Mitra, A. & Riviere, J. (2002) Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. Advanced Drug Delivery Reviews, 54, 825-850.
31. Martinez, M.N., Papich, M.G. & Riviere, J.E. (2004) Veterinary application of in vitro dissolution data and the biopharmaceutics classification system. Pharmacopeial Forum, 30, 2295-2303.
32. Martinez, M., Hunter, R.P., Baynes, R., Bermingham, E., Claxton, R., Cole, C., Del Castillo, J., Gehring, R., Harshman, K., Lainesse, C., Lucas, A., Modric, S. & Robinson, J. (2011) The 2010 AAVPT/EAVPT/ECVPT bioequivalence workshop. Journal of Veterinary Pharmacology and Therapeutics, 34, 105-107.
33. McGilveray, I., Midha, K., Skelly, J., Dighe, S., Doluisio, J., French, I., Karim, A. & Burford, R. (1990) Consensus report from "Bio International '89": issues in the evaluation of bioavailability data. Journal of Pharmaceutical Sciences, 79, 945-946.
34. Melander, A. & McLean, A. (1983) Influence of food intake on presystemic clearance of drugs. Clinical Pharmacokinetics, 8, 286-296.
35. Noonan, P. (2009) Biopharmaceutical limitations of the proposed guidance. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM179424.pdf.
36. Radwan, A., Amidon, G.L. & Langguth, P. (2012) Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity. Biopharmaceutics & Drug Disposition, 33, 403-416.
37. Shah, V.P., Yacobi, A., Barr, W.H., Benet, L.Z., Breimer, D., Dobrinska, M.R., Endrenyi, L., Fairweather, W., Gillespie, W., Gonzalez, M.A., Hooper, J., Jackson, A., Lesko, L.J., Midha, K.K., Noonan, P.K., Patnaik, R. & Williams, R.L. (1996) Evaluation of orally administered highly variable drugs and drug formulations. Pharmaceutical Research, 13, 1590-1594.
38. Singh, B. (2005) A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio, and partition coefficient (Log P) for orally active drugs administered as immediate-release formulations. Drug Development Research, 65, 55-75.
39. Yu, L.X. (2008) Pharmaceutical quality by design: product and process development, understanding, and control. Pharmaceutical Research, 25, 781-791.
40. Yu, L., Bunge, A. & Wilkin, J. (2003) Bioequivalence of topical products - discussion points, food and drug administration advisory committee for pharmaceutical science. Available from: http://www.fda.gov/ohrms/dockets/ac/03/slides/3996s2.htm (accessed 23 March 2013).